A Phase 1a/1b Trial in Relapsed/Refractory Small Cell Lung Cancer to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a Fenretinide Phospholipid Suspension (12.5 mg/mL) for Intravenous Infusion

This study evaluates a fenretinide phospholipid suspension for the treatment of small cell lung cancer (SCLC).

开始日期2025-10-15

申办/合作机构-

NCT07149220

/ Recruiting临床1期IIT

Safety and Chemopreventive Efficacy of Fenretinide Mucoadhesive System in Subjects With Premalignant Oral Intraepithelial Neoplasia (OIN) Lesions: In Conjunction With Pharmacokinetic Assessment in Healthy Subjects.

The goal of this clinical trial is to determine the effect of a mucoadhesive system that releases the vitamin A derivative, fenretinide (FMS), on precancerous surface epithelial (lining tissue inside your mouth) changes. Specifically, does application of the FMS induce specific changes: 1) reduction in the clinical size, 2) reduction in the histologic grade of precancerous changes (determined by microscopic examination), 3) reduce the nuclear LOH events (changes in copy number of key genes to prevent oral cancer).
The first part of this study entails a single FMS application to persons having their wisdom teeth removed. This study is done to confirm how long the FMS needs to remain in place to release the cancer-preventive agent.
Participants will: 1) Have the FMS applied over the impacted wisdom tooth for 15 minutes, 2) FMS is removed, saliva is collected, and blood is drawn from a vein in the arm. 3) Tissue overlying the impacted wisdom tooth is removed and analyzed.
The second, multi-FMS application entails patients who have precancerous oral surface epithelial changes. These patients will have: 1) a piece of the precancerous tissue removed (biopsy) and examined under a microscope to ensure the diagnosis. Blood is drawn from a vein in the arm., 2) One week after the biopsy, return to discuss the results. If the changes are precancerous, this person will be given FMS to apply to the site twice a day. 3) Patients return every 7 to 10 days (for a total of six weeks) for an oral exam and clinical pictures, return the FMS, and obtain new FMS for the upcoming week., 4) At week 3 (midway), blood is drawn from a vein in the arm., 5) After the six weeks of treatment, clinical pictures are obtained, blood is drawn from a vein in the arm and all of the remaining treated tissue is completely removed. The patient is securely contacted and results are discussed. 6) Approximately 6 weeks after the final surgery, patients return for a complete oral examination and clinical pictures are obtained.

开始日期2025-09-01

申办/合作机构

The Ohio State University

[+1]

NCT06528457

/ Active, not recruiting临床2期

A Phase 2, Randomized, Double Blind, Placebo-Controlled Study to Examine the Prophylactic and Treatment Effects of a Single Dose Level of Oral Fenretinide in a Dengue Virus Challenge Model

This randomized, placebo controlled single center study examines the extent to which 600 mg/m2/day of orally administered ISLA101 (fenretinide), given prophylactically or therapeutically, may reduce or eliminate signs and symptoms of dengue virus (DENV) infection over 29 days following subcutaneous challenge of healthy subjects with 'Dengue 1 Live Virus Human Challenge' (DENV-1-LVHC). Humoral and cellular immune responses, both innate and adaptive, circulating virus, and changes in clinical laboratory measures will also be examined.

开始日期2024-09-05

申办/合作机构

Island Pharmaceuticals Ltd.

100 项与芬维A胺相关的临床结果

登录后查看更多信息

100 项与芬维A胺相关的转化医学

登录后查看更多信息

100 项与芬维A胺相关的专利（医药）

登录后查看更多信息

1,291

项与芬维A胺相关的文献（医药）

2025-08-01·Current Drug Delivery

Development of Mixed Micelles for Enhancing Fenretinide Apparent Solubility and Anticancer Activity Against Neuroblastoma Cells

Article

作者: Alfei, Silvana ; Marimpietri, Danilo ; Zuccari, Guendalina ; Zorzoli, Alessia

Introduction/Objectives::

The purpose of the study was to evaluate the suitability of mixed micelles prepared with D-α-tocopheryl polyethylene glycol succinate (TPGS) and 1,2- distearoyl-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000] (DSPE-PEG) to encapsulate the poorly soluble anticancer drug fenretinide (4-HPR).

Methods::

After assaying the solubilization ability of the surfactants by the equilibrium method, the micelles were prepared using the solvent casting technique starting from different 4-HPR:TPGS: DSPE-PEG w/w ratios. The resulting formulations were investigated for their stability under storage conditions and upon dilution, modelling the reaching of physiological concentrations after intravenous administration. The characterization of micelles included the determination of DL%, EE %, particle size distribution, Z-potential, and thermal analysis by DSC. The cytotoxicity studies were performed on HTLA-230 and SK-N-BE-2C neuroblastoma cells by the MTT essay.

Results::

The colloidal dispersions showed a mean diameter of 12 nm, negative Zeta potential, and a narrow dimensional distribution. 4-HPR was formulated in the mixed micelles with an encapsulation efficiency of 88% and with an increment of the apparent solubility of 363-fold. The 4-HPR entrapment remained stable up to the surfactants’ concentration of 2.97E-05 M. The loaded micelles exhibited a slow-release behaviour, with about 28% of the drug released after 24 h. On the most resistant SK-N-BE-2C cells, the encapsulated 4-HPR was significantly more active than free 4-HPR in reducing cell viability.

Conclusion::

Loaded micelles demonstrated their suitability as a new adjuvant tool potentially useful for the treatment of neuroblastoma.

2025-08-01·EXPERIMENTAL PHYSIOLOGY

Hydroxysteroid 17β‐dehydrogenase 13 (Hsd17b13) knockdown attenuates liver steatosis in high‐fat diet obese mice

Article

作者: Morrice, Nicola ; Mody, Nimesh ; Mahmood, Shehroz ; Milanizadeh, Sara ; Mcilroy, George D. ; Thompson, Dawn ; Rochford, Justin J. ; Whitfield, Philip D. ; Wilson, Sophie

Abstract:

Hydroxysteroid 17β‐dehydrogenase 13 (HSD17B13) loss‐of‐function gene variants are associated with a decreased risk of metabolic dysfunction‐associated steatotic liver disease (MASLD). Our RNA‐seq analysis of steatotic liver from obese mice ± fenretinide treatment identified major beneficial effects of fenretinide on expression of hepatic genes including Hsd17b13. We sought to determine the relationship between Hsd17b13 expression and MASLD and to validate it as a therapeutic target by liver‐specific knockdown. Hsd17b13 expression, which is unique to hepatocytes and associated with the lipid droplet, was elevated in multiple models of MASLD and normalised with the prevention of obesity and steatotic liver. Direct, liver‐specific, shRNA‐mediated knockdown of Hsd17b13 (shHsd17b13) in high‐fat diet (HFD)‐obese mice, markedly improved hepatic steatosis with no effect on body weight, adiposity or glycaemia. shHsd17b13 decreased elevated serum alanine aminotransferase (ALT), serum fibroblast growth factor 21 (FGF21) levels, and markers of liver fibrosis, for example, expression of Timp2. shHsd17b13 knockdown in HFD‐obese mice and Hsd17b13 overexpression in cells reciprocally regulated expression of lipid metabolism genes, for example, Cd36. Global lipidomic analysis of liver tissue revealed a major decrease in diacylglycerols (e.g. DAG 34:3) with shHsd17b13 expression and an increase in phosphatidylcholines containing polyunsaturated fatty acids (PUFA) for example, phosphatidylcholine (PC) 34:3 and PC 42:10. Expression of key genes involved in phospholipid and PUFA metabolism, for example, Cept1, was also reciprocally regulated suggesting a potential mechanism of Hsd17b13 biological function and role in MASLD. In conclusion, Hsd17b13 knockdown in HFD‐obese adult mice was able to alleviate MASLD via regulation of fatty acid and phospholipid metabolism, thereby confirming HSD17B13 as a genuine therapeutic target for MASLD and the development of liver fibrosis.

2025-03-01·Journal of Cosmetic Dermatology

A Functional Skincare Formulation Mixed With Retinyl Propionate, Hydroxypinacolone Retinoate, and Vitamin C on Antiaging and Whitening Han Women in Shanghai, China

Article

作者: Qiao, Jian ; Chen, Min ; Bian, Qianjin ; Zhang, Fan ; Fang, Wei

ABSTRACT:

Background:

Human skin is remodeled as a result of aging. Retinoids (or retinol derivatives) can intervene in this process, which can be optimally formulated and concentrated by providing maximum antiaging effects with minimal irritation.

Aims:

To determine the optimal ratio of two retinol derivatives hydroxypinacolone retinoate (HPR), retinol propionate (RP), and vitamin C (VitC) in dermal remodeling and preventing skin aging, and to investigate their synergistic antiaging and whitening effects in vitro and in vivo.

Methods:

An in vitro model of human skin fibroblast (HSF) was established to evaluate the cellular viability of VitC and/or RP/HPR treatment. We quantified the expression of genes associated with antiaging and retinol receptors in HSFs treated with VitC and/or RP/HPR. The research was conducted on 120 volunteer women to quantify the antiaging efficacy of functional skincare formulation.

Results:

A combination of VitC and RP/HPR at a weight ratio of 40:3 achieved the optimal and safe antiaging performance in vitro. Transcription of aging‐associated genes and the release of elastin and senescence‐associated secretory phenotypes (SASPs) increased significantly after UV irradiation, whereas VitC and RP/HPR cotreatment can inhibit this increase. The synergistic stimulation of VitC and RP/HPR cotreatment showed higher efficacy in the recovery ability of skin injury.

Conclusions:

Our results indicated the advanced skin antiaging and whitening effects of VitC and RP/HPR cotreatment in vitro and in vivo. A combination of VitC and RP/HPR is a potent strategy to postpone skin aging and improve skin whitening for middle‐aged women.

Trial Registration:

ClinicalTrials.gov identifier: 2020‐LS‐023

项与芬维A胺相关的新闻（医药）

2025-04-08

·PRNewswire

SciTech Development Announces 2nd FDA Approval of a Phase 1 a/b IND For ST-001. New IND Targets the Treatment of Relapsed/Refractory Small Cell Lung Cancer Following Its Previous Approval in the Treatment of T-Cell NHL

GROSSE POINTE FARMS, Mich., April 8, 2025 /PRNewswire/ -- SciTech Development, Inc., a clinical-stage oncology company pioneering innovative cancer therapeutics, is thrilled to announce that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for "A Phase 1a/b Trial in Relapsed/Refractory Small Cell Lung Cancer (SCLC) to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a Fenretinide Phospholipid Suspension for Intravenous Infusion." This milestone greenlights SciTech to begin recruiting patients and initiates another Phase 1a/b clinical trial of ST-001, a novel nanoparticle drug designed to deliver fenretinide effectively to cancer cells. The FDA's approval follows a thorough safety review, with the agency stating, "We have completed our safety review of your application and have concluded that you may proceed with your proposed clinical investigation of fenretinide phospholipid suspension (ST-001) for small cell lung cancer." This decision marks a significant step forward in SciTech's mission to address unmet needs in oncology, particularly for patients with relapsed or refractory SCLC, a notoriously aggressive disease with limited treatment options. Leading the trial, as Principal Investigator, is Greg Kalemkerian, MD, a renowned thoracic oncologist at the University of Michigan. "Small cell lung cancer remains a formidable challenge with few effective therapies for patients who relapse or don't respond to initial treatment," said Dr. Kalemkerian. "ST-001 represents a promising approach, and I'm excited to oversee this trial to evaluate its safety and potential for SCLC patients who desperately need new options." ST-001 nanoFenretinide leverages SciTech's patented drug delivery platform to overcome fenretinide's historical bioavailability challenges, delivering high doses intravenously with enhanced efficacy and reduced toxicity. The Phase 1a/b trial will assess the drug's safety, pharmacology, and maximum tolerated dose, paving the way for further development in SCLC and potentially other cancers. Building on prior success in a Phase 1a trial for T-cell non-Hodgkin lymphoma - where ST-001 demonstrated favorable pharmacokinetics and early signs of efficacy - SciTech is preparing to launch the SCLC trial in Q2/3 2025. The company anticipates that this trial will further validate the drug's broad therapeutic potential. "We are thrilled about the FDA's approval of our IND for ST-001 in SCLC," said Earle T. Holsapple, CEO of SciTech Development. "This is a pivotal moment that brings us closer to offering a transformative treatment option for patients facing this devastating disease. "Our team's dedication to advancing ST-001's potential through innovative nanotechnology is showing promising results, and we're eager to see its impact in the clinic." About SciTech Development, Inc. SciTech Development, Inc., headquartered in Grosse Pointe Farms, Michigan, is a clinical-stage pharmaceutical company focused on revolutionizing cancer treatment through its proprietary drug delivery platform. ST-001 nanoFenretinide, its lead candidate, combines fenretinide with biocompatible phospholipids to target hard-to-treat cancers, offering hope to patients worldwide. For more information, please visit or contact: Media Contact: David Schaffer | +1-727-278-8188 | [email protected] Disclaimer: This press release contains forward-looking statements based on current expectations. Actual results may differ due to risks and uncertainties. SciTech undertakes no obligation to update these statements beyond legal requirements. SOURCE SciTech Development, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床1期临床申请

2025-01-13

·PRNewswire

SciTech Development Advances to Next Stage of Clinical Trial for ST-001 nanoFenretinide

**Encouraging Data from Accelerated Trial Supports Progress for T-cell Non-Hodgkin Lymphoma.** DETROIT, Jan. 13, 2025 /PRNewswire/ -- SciTech Development, a clinical-stage pharmaceutical company specializing in oncology, is pleased to announce the initiation of the next stage of its clinical trial for their lead drug candidate, ST-001 nanoFenretinide (ST-001) . This milestone follows the successful completion of the accelerated safety and dose-escalation stage, where ST-001 demonstrated exceptional safety, tolerability, and pharmacokinetic performance. Advancing the Phase 1a Trial with Clear Clinical Objectives The continuation of the ST-001 clinical trial aims to achieve several critical clinical objectives: Confirm that ST-001 achieves previously reported clinical response rates. Determine the pharmacological profile of intravenous fenretinide delivered using SciTech's novel nanoparticle delivery system, designed for drugs with poor water solubility. Determine the recommended treatment dose (RTD) to evaluate disease activity and response rates in the follow-on Phase 1b trial and the planned trial in Small Cell Lung Cancer. "The success of our accelerated Phase 1a trial marks a pivotal milestone, driving ST-001 into the next critical stage of development," said Earle Holsapple, CEO of SciTech Development. "We are thrilled about the potential of ST-001 nanoFenretinide and its promise to transform treatment outcomes for patients battling cancers such as T-cell Non-Hodgkin Lymphoma." About ST-001 nanoFenretinide ST-001 nanoFenretinide is a patented nanoparticle IV formulation that combines the drug fenretinide with biocompatible phospholipids. This groundbreaking new investigational drug overcomes bioavailability challenges, enhances therapeutic efficacy, and minimizes toxicity in cancer patients. Powered by SciTech's advanced delivery platform, ST-001 enables rapid delivery of effective doses of fenretinide to cancer cells, marking a breakthrough in hard-to-treat cancers. Encouraging Early Results in Phase 1a Accelerated Trial During the accelerated stage of the trial, ST-001 achieved significant milestones: Patient Enrollment is Complete for the accelerated stage of the clinical trial marking a significant accomplishment for patients with this rare disease. Therapeutic Responses Observed: Patients demonstrated partial responses and stable disease, marking an important step for trial advancement. Excellent Tolerability for ST-001 across all dose levels to date. Outstanding Pharmacokinetics: The nanoparticle delivery platform overcame longstanding bioavailability challenges, ensuring efficient delivery of fenretinide to tissues. Future Direction for ST-001 nanoFenretinide Building on the success of the accelerated Phase 1a stage, the trial begins detailed evaluation of clinical activity and response rates in T-cell lymphomas. The trial is actively underway at nine renowned medical centers across the country. Click here to learn more about the locations and patient trial criteria. Additionally, a separate trial targeting Small Cell Lung Cancer utilizing ST-001 is scheduled to begin in Q2 2025. About SciTech Development, Inc. SciTech Development, Inc., headquartered in Michigan, is an oncology focused, clinical-stage pharmaceutical company led by a world-class team. SciTech is committed to developing innovative, effective, and affordable cancer therapeutics that address unmet medical needs to bring hope to patients around the globe. To learn about SciTech and our latest advancements, please visit . Read the latest Press Release announcing "Promising Preliminary Results from the Phase 1a Accelerated Trial". Company Contact: David Schaffer Investor Relations [email protected] (727) 278-8118 SOURCE SciTech Development, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床1期

2024-12-19

·PRNewswire

A Success Story: Digital Opinion Leader Analysis for Cystic Fibrosis Treatments | DelveInsight

A case study on how a pharmaceutical company specializing in cystic fibrosis treatments turned to DelveInsight for comprehensive analysis and insights into the digital cystic fibrosis landscape in the UK. DelveInsight identified key Digital Opinion Leaders (DOLs) and synthesized their opinions, enabling the client to strategically leverage these insights for drug development, marketing, and patient advocacy, ensuring a competitive edge in the cystic fibrosis market. LAS VEGAS, Dec. 19, 2024 /PRNewswire/ -- DelveInsight, a leader in healthcare competitive intelligence and consulting company, published a success study on Digital Opinion Leader (DOL) Analysis in the Cystic Fibrosis Market . A pharmaceutical company specializing in cystic fibrosis treatments approached DelveInsight to conduct an in-depth analysis of DOLs in the UK. The client sought to identify key digital influencers and understand their perspectives on cystic fibrosis treatments, leveraging these insights to inform drug development, marketing strategies, and patient advocacy efforts. Cystic fibrosis is a life-limiting autosomal recessive genetic disorder that primarily affects the lungs and digestive system, caused by mutations in the CFTR gene. According to DelveInsight's latest Cystic Fibrosis Market and Epidem Forecast Report, the estimated total diagnosed prevalent cases of cystic fibrosis in the 7MM in 2023 were ~68K cases. The UK had the highest number of diagnosed cystic fibrosis cases, with nearly 11K, followed by France with 7.5K and Germany with 7K. In the EU4 and the UK, the cystic fibrosis market size was nearly USD 7 billion, accounting for almost 39.4% of the total 7MM market size in 2023. This is expected to increase significantly by 2034. Download the Sample Report to Explore Future Trends in the Cystic Fibrosis Market In the field of cystic fibrosis, DOLs play a significant role in shaping perceptions and influencing the direction of treatment, policy, and patient care. These are influential healthcare professionals or researchers who have an active online presence and contribute to discussions, research, and advocacy. For pharmaceutical companies developing cystic fibrosis treatments, understanding the DOL landscape is crucial for gaining insights into market dynamics and stakeholder perceptions and identifying strategic opportunities for drug development, marketing, and patient advocacy. Several medications have been approved to manage cystic fibrosis, with therapies targeting the CFTR protein to correct its defects. One of the most groundbreaking treatments is TRIKAFTA, a combination of elexacaftor, tezacaftor, and ivacaftor, which has revolutionized cystic fibrosis treatment by improving lung function in patients with specific genetic mutations. Other notable drugs include SYMDEKO (tezacaftor/ivacaftor) and ORKAMBI (lumacaftor/ivacaftor), which also target the CFTR protein. These therapies aim to address the root cause of the disease, improving symptoms and quality of life for patients. However, despite these advancements, the current treatment landscape still faces challenges, such as variability in treatment efficacy and accessibility to newer therapies for certain patient populations. The pipeline for cystic fibrosis treatments continues to evolve, with several promising drugs in the cystic fibrosis pipeline. Ensifentrine (Verona Pharmaceuticals) is a dual inhibitor of the enzymes responsible for inflammation and mucus production in the lungs, showing potential as an add-on therapy for patients with CF. VX-121/TEZ/VX-561 (Vertex Pharmaceuticals) is another exciting treatment, combining triple therapy to enhance CFTR function and improve lung function. LAU-7b (Laurent Pharmaceuticals Inc.) aims to restore CFTR function and reduce inflammation. Lonodelestat (Pari Pharma GmbH) is being investigated for its ability to reduce neutrophil elastase and inflammation in the lungs of CF patients. These drugs, if successful, could significantly improve treatment options and outcomes for CF patients. Several companies are at the forefront of developing treatments for cystic fibrosis. Eloxx Pharmaceuticals, Inc. focuses on treatments that aim to restore protein function in CF patients with specific genetic mutations. Vertex Pharmaceuticals is a leader in the CF market, with therapies like TRIKAFTA and ongoing pipeline developments. Santhera Pharmaceuticals is exploring potential treatments to address pulmonary issues in CF patients. DelveInsight helped the client by curating insights from the digital cystic fibrosis landscape and analyzing the opinions of key digital influencers. By identifying and analyzing these DOLs, DelveInsight provided actionable insights and strategic recommendations for the client. The company gained a deeper understanding of the market dynamics, stakeholder perceptions, and the evolving digital landscape surrounding cystic fibrosis. These insights were invaluable for informing drug development strategies, understanding the gaps, patient burden,, and patient advocacy initiatives. Armed with comprehensive information on DOLs and their impact, the client was better equipped to make informed decisions, enhance patient engagement, and improve the overall market approach for cystic fibrosis treatments. Our client approached us with multiple objectives: Understand the DOL Landscape in the UK for cystic fibrosis. Identify Key Digital Opinion Leaders influencing discussions about cystic fibrosis. Analyze the Opinions of DOLs on treatment options and emerging therapies. Leverage Insights to refine drug development, marketing strategies, and patient advocacy efforts. Outcome of DelveInsight's Digital Opinion Leader Analysis: We identified and profiled key digital opinion leaders (DOLs) in the UK cystic fibrosis community, focusing on those with strong online presence, high engagement, and CF expertise. Through content analysis, we gained insights into opinions, trends, and key areas like treatment, patient care, advocacy, and research within the CF community. We mapped the CF digital ecosystem, highlighting connections and interactions between DOLs and stakeholders revealing network dynamics and engagement patterns. We assessed the impact of DOLs using metrics like follower count, engagement rate, and content virality, helping clients prioritize engagement strategies and collaborations. DelveInsight specializes in comprehensive Key Opinion Leader (KOL) and Digital Opinion Leader (DOL) opinion analysis, offering deep insights into industry trends, expert perspectives, and influencer dynamics. Our expertise enables clients to identify and understand the nerve of the trends by providing analysis through the most impactful thought leaders and digital influencers. By leveraging our tailored strategies and data-driven approaches, we help businesses strengthen their approach, refine decision-making, and amplify their market impact. Connect with us today to explore how we can support your specific needs and discuss opportunities for strategic engagement. Request a Proposal Now ! Why Choose DelveInsight? DelveInsight offers comprehensive expertise in the respiratory disease domain, providing in-depth market research, consulting services, and pipeline analysis tailored to the evolving needs of the industry. With a sharp focus on respiratory conditions, DelveInsight delivers robust reports covering emerging therapies, market trends, competitive landscapes, and unmet needs. DelveInsight's respiratory-specific solutions empower stakeholders to make data-driven decisions, optimize their R&D efforts, and seize growth opportunities in the dynamic and rapidly advancing respiratory disease market. Market Assessment Services in the Genetic Disorders Segment, DelveInsight, provide a 360-degree view of the market landscape. Our expertise includes epidemiology-based market forecasts up to 2034, offering precise insights into current and future market share uptake of emerging therapies. These forecasts, combined with detailed analyses of emerging trends, competitive dynamics of the pipeline therapies, and unmet needs, enable stakeholders to strategize effectively and identify growth opportunities. Whether it's the pipeline analysis, pricing strategies, or competitive benchmarking, DelveInsight delivers actionable intelligence tailored to your goals. Contact us Today to discuss how our services can drive success in your endeavors within the genetic disorder market. Competitive Intelligence Services Tailored to Genetic Disorder Domain: DelveInsight's competitive intelligence services provide real-time, accurate insights across the different therapeutic domains and genetic disorders being one of our fortes, providing detailed insights into advancements across rare and inherited conditions such as cystic fibrosis, Duchenne muscular dystrophy, and sickle cell anemia etc to name a few. Our services analyze competitors' pipelines, clinical trial progress, gene and cell therapy innovations, and market entry strategies, as well as regulatory updates and patent landscapes specific to genetic disorders. This intelligence enables stakeholders to identify emerging threats, uncover growth opportunities, and develop targeted strategies to remain competitive in this evolving therapeutic area. Connect with us today to explore how we can help you succeed in the genetic disorders market. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform , PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准

100 项与芬维A胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D04162	芬维A胺	-	DB05076

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
新冠肺炎后遗症	临床3期	加拿大	Laurent Pharmaceuticals, Inc.	2023-11-20
新型冠状病毒感染	临床3期	美国	Laurent Pharmaceuticals, Inc.	2020-06-29
BRCA突变阳性乳腺癌	临床3期	意大利	Istituto Europeo di Oncologia Srl	2009-12-01
HR阳性乳腺癌	临床3期	美国	Eastern Cooperative Oncology Group	1995-10-01
乳腺癌	临床3期	-	Johnson & Johnson	-
乳腺癌	临床3期	-	Laurent Pharmaceuticals, Inc.	-
登革热	临床2期	美国	Island Pharmaceuticals Ltd.	2024-09-05
囊性纤维化	临床2期	美国	Laurent Pharmaceuticals, Inc.	2018-11-05
囊性纤维化	临床2期	澳大利亚	Laurent Pharmaceuticals, Inc.	2018-11-05
囊性纤维化	临床2期	加拿大	Laurent Pharmaceuticals, Inc.	2018-11-05

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04234048 (PRNewswire) 人工标引	临床1期	T细胞淋巴瘤	-	ST-001	憲膚衊繭壓積鑰鬱顧鏇(顧網鏇窪築鏇觸選膚鑰) = earlier-than-anticipated stable disease and partial responses - one initial and one confirmed. 蓋齋襯艱製簾範壓獵醖 (衊觸簾壓獵鑰廠顧積鏇 ) 更多	积极	2024-12-03
NCT03265288 (APPLAUD, CTgov)	临床2期	囊性纤维化	166	LAU-7b (LAU-7b)	夢繭鑰膚簾繭獵網選範(繭構膚衊廠壓選鏇淵膚) = 鹹鏇窪齋憲壓衊鏇顧醖築餘廠構衊淵餘憲顧積 (憲襯壓網襯築齋窪積鬱, 遞築獵蓋膚鹽夢糧憲觸 ~ 顧糧壓觸鏇餘膚網膚願) 更多	-	2024-10-09
				Placebo oral capsule (Placebo)	夢繭鑰膚簾繭獵網選範(繭構膚衊廠壓選鏇淵膚) = 廠膚鹹網膚夢鹹製蓋選築餘廠構衊淵餘憲顧積 (憲襯壓網襯築齋窪積鬱, 網齋鏇遞齋餘齋獵遞簾 ~ 鹽壓艱構願鏇繭鏇齋鑰) 更多
NCT01553071 (Phase I trial of intravenous fenretinide (4-HPR) plus safingol in advanced malignancies, Pubmed \| Cancer Chemother Pharmacol)	临床1期	晚期癌症	16	Fenretinide	願獵壓簾淵觸築餘窪觸(憲鹹夢遞襯製繭網顧艱) = 窪構鑰製鏇構願醖鏇觸顧鏇遞遞醖構遞艱窪衊 (糧構夢憲憲鏇網鏇積糧 )	不佳	2023-08-01
NCT03265288 (APPLAUD, Biospace) 人工标引	临床2期	囊性纤维化	166	LAU-7b	繭蓋鑰齋繭顧艱築遞繭(淵廠廠遞築窪構鬱顧淵): difference = 1.23, P-Value = 0.0486	积极	2022-11-03
				Placebo
NCT00546455 (CTgov)	临床2期	胰岛素抵抗 \| 肝炎 \| 代谢功能障碍相关的脂肪肝病 ... 更多	21	Fenretinide (A- Fenretinide)	鏇鏇網積積鹹顧艱憲築(艱獵淵衊鑰鹽鬱鬱遞夢) = 膚憲鹽窪糧觸窪鬱鹹醖築壓衊範選衊鏇糧襯襯 (衊衊壓築壓觸網鹹鏇餘, 膚膚衊範蓋製襯構製淵 ~ 鏇齋網鬱觸鏇憲遞蓋製) 更多	-	2021-02-10
				placebo (B-Placebo)	鏇鏇網積積鹹顧艱憲築(艱獵淵衊鑰鹽鬱鬱遞夢) = 觸範網繭願築範鹹廠構築壓衊範選衊鏇糧襯襯 (衊衊壓築壓觸網鹹鏇餘, 顧積構範窪窪鬱製繭積 ~ 選夢餘鑰窪蓋願淵醖廠) 更多
NCT00104923 (Pubmed \| Clin Cancer Res) 人工标引	临床1期	血液肿瘤	29	Fenretinide	夢製鬱艱鏇糧築鹹襯顧(獵範構淵觸膚夢鏇衊遞) = 壓顧鬱蓋衊鬱製顧膚蓋網觸壓簾鏇憲齋衊淵選 (構衊蓋網範遞鑰簾積網 )	积极	2017-08-15
				Fenretinide (patients with response-evaluable peripheral T-cell lymphomas)	壓醖鑰壓鏇壓廠願醖廠(範憲窪襯範糧選淵醖膚) = 夢醖遞夢憲憲鏇醖願遞製衊襯積構襯簾鑰夢觸 (鏇蓋齋蓋膚繭壓範顧獵 ) 更多
NCT00288067 (Pubmed \| Int J Radiat Oncol Biol Phys) 人工标引	临床1/2期	套细胞淋巴瘤 \| B细胞淋巴瘤	32	fenretinide	鹹築簾糧網廠範廠鏇蓋(艱襯顧範鹽憲製窪糧齋) = No dose-limiting toxicities were observed. 窪築範製廠網繭壓網觸 (蓋壓鏇網鹹齋膚鬱鏇衊 ) 更多	积极	2017-02-01
				fenretinide+rituximab
NCT00080899 (CTgov)	临床2期	复发性前列腺癌 \| 非转移性前列腺癌 \| 前列腺腺癌	23	N-(4-hydroxyphenyl) retinamide \[4-HPR\]	範願鏇艱顧製鹽選艱齋 = 遞簾夢艱構鏇選艱廠鹽窪襯夢廠鑰憲襯餘簾鹹 (鏇壓範衊簾醖範夢簾鏇, 壓齋餘網網鹹衊製艱衊 ~ 鬱遞鹹夢鏇簾遞網構構) 更多	-	2015-03-06
NCT00288067 (CTgov)	临床1/2期	复发性边缘区淋巴瘤 \| 滤泡性淋巴瘤 \| 急性淋巴细胞白血病 ... 更多	32	Fenretinide+Rituximab (Fenretinide and Rituximab)	廠簾襯衊糧遞衊鏇築齋 = 獵觸蓋製廠鏇鬱鬱淵簾觸觸鑰構餘鑰繭餘構窪 (鏇繭夢積範觸築窪衊糧, 簾獵齋淵願鹹淵網鬱鹹 ~ 構網遞膚窪鏇製艱網顧) 更多	-	2014-10-06
				Fenretinide+Rituximab (Fenretinide and Rituximab (Rituximab Naive))	艱齋衊遞夢選廠廠觸範 = 窪網範齋鹹衊窪壓齋積積餘襯繭鬱顧淵構鑰構 (壓壓鹹鬱範窪製獵衊鏇, 憲蓋鬱鬱範選鹹艱選膚 ~ 淵襯鬱廠鬱壓膚獵遞鹽)
NCT00295919 (N2004-04, ASCO2014)	临床1期	神经母细胞瘤	80	4-HPR/LXS oral powder	鹽顧醖餘鬱膚獵鹽壓壓(憲遞衊蓋衊襯鑰齋廠選) = 築顧廠壓夢蓋鑰蓋鑰鬱築遞網顧網糧鹹窪繭鹹 (願廠鏇壓夢餘遞願範襯, 1.35 ~ 36.9+) 更多	-	2014-05-20
				Ketoconazole	淵壓蓋網製憲壓遞鑰製(鏇襯製齋鏇鏇鏇簾艱遞) = 鹽憲壓鏇網積齋獵製糧艱繭餘網鑰淵淵鹹憲糧 (鏇夢衊膚遞願顧鏇範積, 14.6 ~ 22.1)